An annual infusion of zoledronic acid may be an effective treatment for postmenopausal osteoporosis.
In this study, zoledronic acid infusions given at intervals of up to one year produced effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates and with proven efficacy against fractures.
Bisphosphonates are effective agents for the management of osteoporosis. However, their low bioavailability and low potency necessitate frequent administration on an empty stomach. This, in turn, may reduce compliance. Gastrointestinal intolerance limits maximal dosing.
Until now, although intermittent intravenous treatments have been used, the optimal doses and dosing interval have never been systematically explored. These researchers examined five intravenous regimens of the potent bisphosphonate zoledronic acid (a total of one to four mg in one to four doses over the course of one year) and compared them with placebo in postmenopausal women with low bone mineral density. …